The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


Market Cap




About Aduro BioTech

Aduro is advancing multiple therapeutic and prophylactic vaccines for cancer and infectious diseases based on its attenuated Listeria monocytogenes vaccine platforms. The company is also advancing a new program towards clinical evaluation that utilizes targeted small molecule immune modulators that have broad application for vaccine design. The company's Listeria platform has been validated by publications that illustrate the platform's combination of safety and potency.

Aduro BioTech Headquarter Location

740 Heinz Ave

Berkeley, California, 94710,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aduro BioTech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aduro BioTech is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aduro BioTech Patents

Aduro BioTech has filed 64 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Immune system, Clusters of differentiation, Immunology, Monoclonal antibodies, Molecular biology


Application Date


Grant Date



Related Topics

Immune system, Clusters of differentiation, Immunology, Monoclonal antibodies, Molecular biology



Latest Aduro BioTech News

09:00 EDT Global Cancer Vaccines Market Analysis Report 2022-2030 Featuring Major Players - GSK, Merck, Aduro Biotech, Astrazene...

Apr 19, 2022

News provided by Share this article Share this article The global cancer vaccines market is expected to grow from $4.47 billion in 2021 to $5.29 billion in 2022 at a compound annual growth rate (CAGR) of 18.2%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $9.36 billion in 2026 at a CAGR of 15.3%. Major players in the cancer vaccines market are GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc., Dendreon, Astellas Pharma Inc., Sanofi Pasteur, Sanpower Group and CSL Limited. The cancer vaccines market consists of sales of vaccines used for the treatment of cancers and related services by entities (organizations, sole traders and partnerships) that produce vaccines for cancer treatment. Cancer treatment vaccines, also called therapeutic vaccines are a type of immunotherapy, which stops tumor growth, destroys cancer cells and prevents the reoccurrence of cancers. The market consists of revenue generated by the company's manufacturing cancer vaccines by the sales of these products. The main types of cancer vaccines are preventive cancer vaccines and therapeutic cancer vaccines. Therapeutic vaccinations aid in the recognition of a virus or malignant cell by the immune system. The different types of cancers include prostate, cervical, colorectal, throat, others and involves various technologies such as dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, viral vector & DNA cancer vaccines. The several sectors include cancer treatment centers, research institutes. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer vaccines market during the forecast period. According to the American Cancer Society, there were 1,7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer vaccines market over the coming years. Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of cancer vaccines manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes, which is affecting the cancer vaccine sales. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027. This trend is expected to continue during the forecast period and limit the demand for cancer vaccines. Companies in the cancer vaccines market are increasingly investing in preventive or prophylactic vaccines for cancer prevention. Prophylactic vaccines are designed to build immunity in a patient. A prophylactic or preventative vaccine involves introducing antigens into a person's body. According to the World Health Organization, cervical cancer was reported as the second-most common cancer in women with an estimation of 84% new cases worldwide. So far, there are 3 HPV vaccines currently present for the prophylaxis of cancers. Two among these will protect against both HPV 16 and HPV 18, which causes 70% of cervical cancer and the third vaccine prevents 3 more oncogenic HPV types, which further causes 20% of cervical cancers. These three vaccines include Gardasil and Gardasil9 by Merck and Cervarix by GSK. In April 2019, Bayer, through its investment arm Leaps by Bayer, has invested in a US-based biotechnology firm Khloris Biosciences, which is focused on developing prophylactic anti-cancer vaccines. In May 2020, Merck, a US-based pharmaceutical company, acquired Themis Bioscience for an undisclosed amount. The acquisition is expected to complement Merck's capabilities in the development, manufacturing, and distribution of vaccines. Themis Bioscience is a pharmaceutical company that manufactures vaccines and immune-modulatory therapies developed using the measles virus vector platform based on a vector originally. Key Topics Covered:

Aduro BioTech Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aduro BioTech Rank

  • When was Aduro BioTech founded?

    Aduro BioTech was founded in 2000.

  • Where is Aduro BioTech's headquarters?

    Aduro BioTech's headquarters is located at 740 Heinz Ave, Berkeley.

  • What is Aduro BioTech's latest funding round?

    Aduro BioTech's latest funding round is IPO.

  • How much did Aduro BioTech raise?

    Aduro BioTech raised a total of $173.19M.

  • Who are the investors of Aduro BioTech?

    Investors of Aduro BioTech include Helion Venture Partners.

  • Who are Aduro BioTech's competitors?

    Competitors of Aduro BioTech include Hawaii Biotech, Aerie Pharmaceuticals, Ocera Therapeutics, Ascendis Pharma, VLST Corporation and 12 more.

You May Also Like


TechnoVax is a privately held biotechnology company and specializes in vaccine development. The company aims to begin clinical trials within the next 18 months.

Osprey Pharmaceuticals

Osprey Pharmaceuticals is a privately held biotechnology company focused on developing and commercializing a first-in-class family of therapeutic proteins (Leukocyte Population Modulators) capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The company's proprietary LPMs selectively and systematically destroy disease-related leukocytes by infiltrating the chemokine system that regulates the movement and activity of leukocytes.


Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

FIBREX Medical

FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company is focused on pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. Per FIBREX, while inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction.


AgaPharm is developing a prescription eye drop for Diabetics. The drug aims to offer a simple, low-cost treatment that can deliver a safe and effective dose to the eye, preventing or slowing down the onset of diabetic blindness and cataract. The company's Research Partner is the Biotechnology Research Institute at the National Research Council of the Government of Canada.

Noveome Biotherapeutics Logo
Noveome Biotherapeutics

Noveome Biotherapeutics is regenerative medicine company focused on the research, development and clinical use of its technology platform, derived from human placental cells. This platform provides a new approach to tissue regeneration and repair in a wide range of medical conditions. Noveome's technology platform is derived from a population of cells isolated from full-term placental tissue that is normally discarded following delivery of a baby. There is no interruption in the development of the baby to procure this tissue.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.